Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.

Front Immunol 2020 5;11:575258. Epub 2020 Nov 5.

Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States.

is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.575258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674585PMC
November 2020

Publication Analysis

Top Keywords

bladder cancer
12
urothelial bladder
8
era immunotherapy
8
therapeutic target
8
role bladder
4
understood review
4
review role
4
incompletely understood
4
immunotherapy incompletely
4
utility marker
4
marker target
4
context immunotherapy
4
cancer discuss
4
preclinical clinical
4
selection factor
4
factor therapeutic
4
target era
4
patient selection
4
effectiveness patient
4
cancer utility
4

Similar Publications